Kornimate/medical-research-clean huggingface dataset:
rituximab in recurrent iga nephropathy

Conditions: Recurrent IgA Nephropathy

Summary: currently, the treatment options of recurrent iga nephropathy (igan) are conflicting and largely based on expert opinions. consequently, the recent kdigo clinical practice guideline for the care of kidney transplant recipients has concluded that there are no definite strategies for prevention and treatment. however, recurrent igan in the transplanted kidney is common and may contribute to graft loss, in particular, if cresentic formation, extra- or endocapillary proliferation were presented in kidney pathology. herein, the investigators assume that rituximab, anti-cd20 ab agent, can reduce circulating iga with subsequently decrease rate of polymeric forms of iga deposition in glomerular capillaries. therefore, the investigators speculate that rituximab may have potential effect to reduce circulating polymeric forms of iga and slow progression of recurrent igan.

hypothesis: in kidney transplant recipients with active endocapillary proliferation pathology of recurrent igan, an intravenous infusion of 375mg/m2 of rituximab on 4 consecutive monthly dose is superior to conventional therapy in reducing 24-hour proteinuria, and slowing progression of recurrent igan.

Eligibility criteria:
inclusion criteria: * any kidney transplant recipients between the age of 18 and 70 years of age and able to give informed consent * gfr by 24h creatinine clearance (crcl) \>30 ml/min/1.73m² * biopsy proven recurrent iga nephropathy with endocapillary proliferation pattern exclusion criteria: * clinical and histologic evidence of iga combination with other forms of glomerulonephritis * clinical evidence of cirrhosis, chronic active liver disease or known infection with hepatitis b, c or hiv * 24h crcl \<30 ml/min/1.73m² at the time of screening * active systemic infection or history of serious infection within one month of entry * positive pregnancy test or breast feeding at time of study entry * patients receiving \>6 months therapy with oral prednisone \>5mg/day or glucocorticoid equivalent * live vaccine within 28 days of study enrollment.

Keywords: recurrent iga nephropathy rituximab
open-label trial of the use of minocycline in the treatment of asthma

Conditions: Asthma

Summary: the tetracycline minocycline has, in addition to its anti-infective properties, anti-inflammatory properties which may be of use in the treatment of asthma. this study evaluates the benefit of minocycline as add-on therapy for adults with asthma.

adult asthmatic (ages 18 to 75 years) with a history of moderate to severe persistent asthma are given minocycline capsules as add-on therapy for treatment of asthma. treatment is for one year. dosing begins at 150 mg twice daily and can increase every eight weeks by 50mg bid to a maximum of 250 mg twice daily. this is as per patient tolerance as minocycline can cause dizziness and stomach upset, as well as effects of liver enzymes.patients undergo routine blood toxicity screens every two months, at which time spirometry is performed exclusion criteria: pregnant women (adequate contraception in mandated) previous history of hypersensitivity to tetracyclines, chronic liver disease outcome measures: improvement in fev1 and other spirometric parameters, decrease in oral steroid requirements, change in total serum ige, improvement in quality of life

Eligibility criteria:
inclusion criteria: * adults (ages 18 to 75 yrs) * mild to severe asthma * history of or current oral steroid use to control asthma atopy exclusion criteria: * pregnant women

Keywords: minocycline asthma oral steroids ige
to study the safety and efficacy of midodrine with albumin versus albumin alone in hepatic hydrothorax

Conditions: Hepatic Hydrothorax

Summary: hepatic hydrothorax is defined with accumulation of transudate fluid (500 ml) in the pleural cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural diseases. the prevalence is 5-12% the treatment for hydrothorax is diuretics, repeated thoracocentensis, tips and liver transplant.. midodrine increases effective arterial blood volume and also increases renal perfusion.it has also been used in refractory ascitis .it has been shown to mobilise ascitis. in patients who are ineligible for tips and liver transplant there is no data on midodrine and its effects on hydrothorax in cirrhotics.there are also no guidelines on the use of albumin during pleural fluid tapping and the dose to be used. this study is being done to assess the safety and efficacy of midodrine in hydrothorax.


Eligibility criteria:
inclusion criteria: * patients with hepatic hydrothorax * patients with age from 18-75 years * no evidence of cardiac and pulmonary disease exclusion criteria: * renal failure ( creatinine\>2.5mg/dl) * gastrointestinal bleeding * spontaneous bacterial empyema/ peritonitis * patients with urinary retention * intrinsic advanced pulmonary disease (cxr, hrct thorax) * cardiovascular disease (electrocardiogram, 2d echo) * systemic arterial hypertension * presence of hepatocellular carcinoma or portal vein thrombosis, budd chiari syndrome * patients with active untreated sepsis * pregnancy * patients with hepatic encephalopathy * patients eligible for tips * no use of drugs affecting systemic hemodynamics prior to 7 day of enrollment
opioid reduction program for total knee replacement patients

Conditions: Knee Injuries; Knee Injuries and Disorders; Opioid Use

Summary: in the context of prescribed opioids, research suggests that increased exposure is associated with long-term opioid use. orthopedic surgeries are associated with the prescribing of more opioid narcotics than any other surgical specialty, particularly for total knee replacement surgery, which is associated with severe post-operative pain. the proposed project is a randomized clinical trial to explore the efficacy of our total knee replacement opioid reduction program (orp) vs. treatment as usual (tau) in the reduction of opioid use following total knee replacement surgery.

the purpose of the study is to build upon our existing research to: (1) explore the efficacy of a disseminable opioid reduction program (orp) to reduce long-term use of prescribed opioids following tkr surgery, (2) assess whether lower opioid use following surgery is related to better functional recovery, and (3) model opioid use trajectories following tkr surgery (i.e., mmes/week for 12 weeks), which will allow us to examine the factors that characterize at-risk groups. there will be one control arm (treatment as usual or tau) and one experimental arm (opioid reduction program or orp). the experimental arm will receive the intervention material twice. the first session is pre-surgery, and the second session is a shortened "booster" session approximately 2-weeks post-op.

Eligibility criteria:
inclusion criteria: * 18 years or older. * presenting for a total knee replacement (tkr) surgery at campbell clinic which will result in an opioid prescription. * access to a telephone. * able to consent in english. exclusion criteria: * under the age of 18. * contraindications to use of opioid medication. * no access to a telephone. * unable to understand consent materials in english.

Keywords: opioid total knee replacement knee arthroplasty knee injuries prevention analgesics, opioid
onc-leuk-2406: the impact of systematic financial navigation in acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this research is to see how personal financial burden (financial toxicity) related to cancer affects the overall health and quality of life by evaluating the impact of systematic financial navigation in addition to standard financial distress interventions during cancer treatment.

financial navigation (fn) has been increasingly recognized as an important interventional tool with the potential to significantly mitigate the onset, severity, and duration of financial toxicity (ft). there have been several recent pilot studies in this area demonstrating the feasibility and effectiveness of this approach. with the suddenness of onset and high healthcare utilization of an acute leukemia diagnosis, financial navigation early in the disease course may represent an opportunity to reduce the financial distress burden of this disease and improve outcomes. the investigators have chosen to conduct this as a randomized, controlled trial (rct) evaluating the effect of financial navigation (fn) on the patient reported objective measurement of financial toxicity (ft) using the comprehensive score for financial toxicity (cost) measure. this 12-question measure has become the standard for financial toxicity (ft) quantification in the research setting and will allow for direct comparison between the two groups.

Eligibility criteria:
inclusion criteria: 1. ability to understand and willingness to sign an irb-approved informed consent. 2. age 18-64 years at the time of consent 3. initial diagnosis of acute myeloid leukemia (aml) per investigator note: date of initial diagnosis is the date of the bone marrow biopsy 4. planned intensive induction chemotherapy note: it is acceptable if chemotherapy has been initiated at the time of enrollment as long as it is within 4 weeks of diagnosis 5. ability to read and understand the english and/or spanish language(s) 6. as determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study. exclusion criteria: 1. diagnosis of acute promyelocytic leukemia 2. unwilling to receive induction chemotherapy for aml 3. previous treatment for hematologic malignancy 4. prior allogeneic hematopoietic stem cell transplant

Keywords: financial navigation financial toxicity
effects of bran size on glycemic responses

Conditions: Potential Abnormality of Glucose Tolerance; Appetitive Behavior

Summary: this study investigated the effects of bran's particle size on glycemic responses

this study aimed at 1. to determine the gi and gl of three breads and 2. to investigate the effects of bran's particle size on postprandial glycemic response in healthy subjects.

Eligibility criteria:
inclusion criteria: * healthy, non-smoking, non-diabetic men and women, individuals with normal body mass index (bmi; between 18.5 and 24.9 kg/m2) exclusion criteria: * severe chronic disease (e.g. coronary heart disease, diabetes mellitus, kidney or liver conditions, endocrine conditions) * gastrointestinal disorders * pregnancy * lactation * competitive sports * alcohol or drug dependency

Keywords: blood glucose bran particle size glucemic index
oxidative stress on muscle dysfunction in hemodialysis patient

Conditions: Chronic Renal Failure Requiring Hemodialysis

Summary: in hemodialysis patient (hd) a reduction of the skeletal muscle mass and strength has previously been reported. this muscle impairment constitutes an independent prognosis factor in hd patients. oxidative stress and inflammation have been linked to the muscle impairment. the mitochondria is a classical producer and target of reactive oxygen species (ros), and may thus constitute a central actor of the skeletal muscle impairment in hd patients. therefore, the aim of the present study is to investigate the role of the muscle mitochondrial density on the muscle impairment in hd patients, in comparing the muscle mitochondrial density and oxidative stress in hd patients vs. healthy matched controls. in order to assess the effect of the oxidative stress and inflammation on the muscle impairment in hd patients, muscle function assessements will be performed after renal transplantation (which lowers the oxidative stress and inflammation levels) in the hd patient group. no therapeutic intervention will be tested in the present study.


Eligibility criteria:
inclusion criteria: * age between 40-80 years old * less than 150min by week of moderate to vigorous physical activity * chronic renal failure (glomerular filtration rate less than 15ml by min) requiring hemodialysis * patient placed on the kidney transplant waiting list of montpellierchu * no indication against temporary kidney transplant * review cardiovascular older than two years * patient not under guardianship or trusteeship * clinically stable state absence or recent infection within 3 months prior to inclusion absence of progressive neoplasia no recent acute decompensation of chronic disease (thrust of heart failure, respiratory decompensated cirrhosis). absence of recent stroke * musculoskeletal and neurological states of the lower limbs which allow the realization of the proposed functional tests. * patient has given written informed consent * absence of congenital or genetic degenerative muscle disease exclusion criteria: * terminal chronic renal failure without replacement therapy * local anesthesic hypersensibility * corticosteroid treatment upper than 3 month * copd * oral anticoagulants * previous renal transplantation * subject not affiliated with a social security scheme, beneficiary or not such a plan * major subject protected by law or unable to consent under article l 1121-8 of the public health code * vulnerable person under article l.1121-6 of the public health code

Keywords: hemodialysis muscle dysfunction mitochondria oxidative stress inflammation renal transplantation
validation in humans of genes involved in alcohol drinking, stress-induced alcohol drinking and relapse

Conditions: Alcohol Drinking

Summary: aim of the project is to validate and functionally characterize the combined impact of candidate genes and stress exposure on drinking in adolescents. lifetime and recent stress experiences and drinking are recorded in a sample of healthy young adults who are genotyped for polymorphisms in candidate genes related to alcoholism. all participants undergo a standard laboratory psychosocial stress test. our hypothesis is that specific genes can be identified which influence drinking by modulating stress response.


Eligibility criteria:
inclusion criteria: * all 18 or 19 year old participants of the mannheim risk children study, i.e. a longitudinal birth cohort study that started in 1986 and had the inclusion criteria given below: * male and female singletons, firstborn to their mothers between february 1st, 1986 and february 28th, 1988, consecutively recruited from 2 obstetric and 4 children's hospitals of the rhine-neckar region, germany. * with no severe physical handicaps, obvious genetic defects, or metabolic diseases. * with german-speaking caucasian parents. * falling into one of 3 predefined groups with absent, moderate or high pre- and perinatal risk, operationalized by low gestational age at birth, low birth weight, and severity of the following: preterm labor, eph-gestosis, perinatal asphyxia, seizures, respiratory distress syndrome, perinatal sepsis. * falling into one of 3 predefined groups with absent, moderate or high psychosocial risk, operationalized by a family risk index measuring the presence of 11 adverse family factors covering characteristics of the parents (e.g., psychiatric disorders), the partnership (e.g., disharmony), and the family environment (e.g., overcrowding)during a period of one year prior to birth. exclusion criteria: * intelligence quotient or motor quotient below 70, or presence of severe neurological disorder such as infantile cerebral palsy, at age 15. * women with known pregnancy. * any physical of psychiatric disease requiring treatment * incapable to give informed consent or to answer questionnaires in writing * recent use of illegal drugs

Keywords: alcoholism risk factors adolescence stress test hpa system family adversity candidate genes cortisol adrenocorticotrophin
use of different diagnostic coronary catheters over the radial access - the uddc - radial trial

Conditions: Stable Coronary Heart Disease

Summary: there is no evidence from prospective randomized clinical trials regarding the performance of conventional (two-catheter-concept; tcc) versus one-catheter-concepts (occ) for invasive coronary angiography over the radial access. the aim of the present trial is to evaluate the efficacy and safety of different one-catheter concepts by use of the blk and tiger catheter compared to a tcc using standard judkins catheters in diagnostic coronary angiography via transradial access. patients with stable angina pectoris will be randomly assigned to coronary angiography performed with the blk or tiger (occ) or judkins catheters (tcc). the primary endpoint is coronary angiography duration.

the aim of the present trial is to evaluate the efficacy and safety of a one-catheter concept using the blk (terumo, somerset, usa) or the tiger catheter (terumo, somerset, usa) compared to the standard judkins catheters in diagnostic coronary angiography by the transradial access. patients with stable angina pectoris will be randomly assigned to coronary angiography performed with the blk (group i), tiger (group ii) or judkins catheters (group iii). primary endpoint is the time duration (sec) that is necessary to perform complete coronary angiography including 6 different projections for the left-coronary system and 3 different projections of the right-coronary-system. secondary endpoints will cover safety and imaging quality of the different catheter systems.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years and ≤ 95 years * body weight \> 60kg exclusion criteria: * acute coronary syndrome or cardiogenic shock * contraindications for transracial access such as absence of radial pulse or abnormal allen test * prior unsuccessful transradial coronary angiography * estimated glomerular filtration rate \<40 ml/kg/min * patients not able to give informed consent * participation in another trial
superiority of on-demand prep versus pep on using doxycycline for preventing sti in msm

Conditions: Sexually Transmitted Diseases, Bacterial; Syphilis; Gonorrhea; Chlamydia

Summary: the goal of this clinical trial is to compare the effectiveness of doxycycline taken for on-demand pre-exposure prophylaxis (doxyodprep) and its post-exposure use (doxypep) in preventing bacterial sexually transmitted infections (sti), including chlamydia, gonorrhoea, and syphilis among men who have sex with men (msm). the main questions it aims to answer are: 1. is doxyodprep superior to doxypep? 2. are both regimens safe? 3. does the msm community accept the use of doxycycline to prevent bacterial sti? participants will be asked to take doxycycline according to the study arm they are randomly assigned to, and attend regular clinical follow-ups during the 2-year observation period. researchers will compare the bacterial sti incidences between the two groups to see if doxyodprep is superior to doxypep.

participants would be randomly assigned to either doxyodprep or doxypep arm, and be instructed to take doxycycline with the respective dosing schedule. they would be followed up for 24 months for nucleic acid amplification test (naat) and antibody tests against bacterial sti, namely chlamydia, gonorrhoea, and syphilis. the subjects and investigators would not be blinded due to its open-label nature, as the two arms' dosing schedules are different. participants in the doxyodprep arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. if they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex. participants in the doxypep arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex. at each clinic visit, urine, and pharyngeal and rectal swabs would be self-collected on-site by the participants following instructions. pill count would be performed for each follow-up visit.

Eligibility criteria:
inclusion criteria: * has had sex with another male in the past six months * normally reside in hong kong * can communicate in written and spoken chinese or english * willing and able to give written informed consent * being willing and able to attend scheduled study clinic visits * at risk of sti (had condomless sex with more than one man in the past 12 months, history of sti diagnosis in the past 12 months, inclination to have condomless sex, and other hiv-prep-eligible criteria) exclusion criteria: * being allergic to tetracycline class medicines * currently taking medications that are contraindicated with doxycycline * using antibiotics for more than 14 days in the month preceding enrolment

Keywords: doxycycline men who have sex with men sexually transmitted infections
time performance of scoop stretcher versus vacuum mattress for prehospital spinal stabilization

Conditions: Immobilization

Summary: a simulation-based randomized controlled trial was designed with the objective to assess the time needed to achieve spinal stabilization using a scoop stretcher compared to a vacuum mattress.

a simulation-based randomized controlled trial was designed with the objective to assess the time needed to achieve spinal stabilization using a scoop stretcher compared to a vacuum mattress. the participants will be recruited among healthcare workers from one emergency medical service. then, the participants will first act as patient and undergo spinal stabilization from an other team, afterwards they will have to complete a spinal stabilization either using a scoop stretcher or a vacuum mattress, depending on allocation regarding randomization. the sessions will be video recorded to allow subsequent assessment.

Eligibility criteria:
inclusion criteria: * registered paramedics or emergency medical technician (emt) actually working in the ambulance service. exclusion criteria: * member of study investigators

Keywords: spinal stabilization prehospital emergency medical services scoop stretcher vacuum mattress spinal cord injury prehospital emergency care
comparison of two protocols for patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: the patellofemoral pain syndrome (pfps) is defined as a painful complaint in the anterior aspect of the knee, although peripatellar pain and / or retropatellar are also common. in general, conservative treatment is the initial option of choice for patients with pfps, however, the lack of a specific causal factor makes it difficult to choose the best treatment so early. this way, the purpose of this study is investigate the effects of the quadriceps femoris strengthening versus hamstring stretching in patients with pattellofemoral pain.


Eligibility criteria:
inclusion criteria: * symptoms of anterior knee pain for at least 1 moth; * average pain level of 3 or more on a 10-cm visual analogue scale during stepping up and down a 25-cm height; * anterior or retropatellar knee pain on at least 2 of the following activities: prolonged sitting, climbing stairs, squatting, running, kneeling, and hopping/jumping; * presence of 2 of the following clinical criteria on assessment: pain during apprehension test, pain during the patellar compression test, and crepitation during the compression test. exclusion criteria: * previous knee surgery or arthritis; * history of patellar dislocation or subluxation, malalignment, or ligament laxity; * patellar tendon pathology or chondral damage; * spinal referred pain; * history of other abnormalities such as leg length inequalities (\>2 cm); * medication as a part of the treatment; * previous physical therapy or acupuncture treatment for the knee within the previous 30 days.

Keywords: pattelofemoral pain syndrome stretching strengthening